Oguz, Mustafa
Lanitis, Tereza
Li, Xiaoyan
Wygant, Gail
Singer, Daniel E.
Friend, Keith
Hlavacek, Patrick
Nikolaou, Andreas
Mattke, Soeren
Funding for this research was provided by:
Bristol-Myers Squibb
Pfizer
Article History
First Online: 17 December 2019
Compliance with Ethical Standards
:
: Funding for this project was provided by Pfizer, New York, NY, USA and Bristol-Myers Squibb, Lawrenceville, NJ, USA.
: Mustafa Oguz, Tereza Lanitis, and Andreas Nikolaou are employees of Evidera, a research and consulting company in the biopharmaceutical industry. In their salaried positions, they work with a variety of companies and are precluded from receiving payment or honoraria directly from these organizations for services rendered. Evidera received payment from Pfizer and BMS for work on this project and article (significant). Gail Wygant, Keith Friend, and Xiaoyan Li are employees of and own stock in BMS (significant). Patrick Hlavacek is an employee of and owns stock in Pfizer (significant). Dr. Soeren Mattke serves on the board of directors of Senscio Systems, Inc. (stock options, modest) and the scientific advisory board of AiCure technologies (stock options, modest), Boston Millennia Partners, and ZanoZano (stock options, modest). He has received consulting fees from AARP (significant), Biotronik (significant), Bristol-Myers Squibb (significant), Eisai (modest), and Defined Health (modest). Dr. Daniel Singer receives research funding from Bristol-Meyers Squibb (significant) and Boehringer Ingelheim (significant), and has provided consulting to Boehringer Ingelheim (significant), Bristol-Myers Squibb (significant), Johnson and Johnson (modest), Merck (modest), and Pfizer (modest).